Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim

Preview text: Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim…

Wednesday, Nov 4, 2026 at 10:45 AM EasternMailchimp

Rakovina TherapeuticsLive tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim

Fit to screenFull size

Using this email in an article? Credit: Rakovina Therapeutics email via They Sent It, with a link to this page. Full-size image

Use this example

Subject: Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
Preview text: Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim…
From: ir@rakovinatherapeutics.com
Brand: Rakovina Therapeutics
ESP: Mailchimp
Sent: Wed Nov 4, 2026, 10:45 AM ET
Size: 48 KB
Images: 1
Links: 10, 1 of them buttons
Subject length: 83 characters

Against Rakovina Therapeutics's usual

Sent in the 10 AM hour, which holds 13% of its emails; 31% arrive in the 4 PM hour. The subject is 83 characters; its average is 70.

Email headers

What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.

From: Rakovina Therapeutics <[email protected]>
Reply-To: Rakovina Therapeutics <[email protected]>
Subject: Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
Date: Wed, 4 Nov 2026 15:45:34 +0000
Message-ID domain: mail148.suw161.rsgsv.net
Return-Path domain: mail148.suw161.rsgsv.net
DKIM signature: d=gmail.mcsv.net s=k2; d=mailchimpapp.net s=k3
Authentication: dkim=pass (gmail.mcsv.net), dkim=pass (mailchimpapp.net), spf=pass (mail148.suw161.rsgsv.net)
List-Unsubscribe: Present, one-click
Mailer: Mailchimp Mailer
Feedback-ID sender: mc

from mail148.suw161.rsgsv.net [198.2.175.148] by our receiving server with ESMTPS
from localhost [127.0.0.1] by mail148.suw161.rsgsv.net with ESMTP

Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype

	Nov 10, 2026 12:27 PM	Announcing our partnership with Artemis AI
	Nov 4, 2026 10:45 AM	Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim (this email)
	Oct 30, 2026 11:32 AM	AI narrows the focus for our brain-targeted cancer drug
	Oct 22, 2026 4:17 PM	kt-5000AI update: what we’ve shown, and what’s next
	Oct 18, 2026 4:14 PM	Rakovina secures exclusivity on kt-5000 target profile · Resent
	Oct 15, 2026 10:30 AM	Rakovina secures exclusivity on kt-5000 target profile
	Oct 1, 2026 4:18 PM	Rakovina partners with Celvion: what it means for our ATR program